Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 15/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 15/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 15/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 11/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4353598 | 0.91 | PIK3CA (0.52) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4350521 | 0.91 | PIK3CA (0.49) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4346609 | 0.90 | PIK3CA (0.48) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4346382 | 0.90 | PIK3CA (0.48) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4352345 | 0.89 | PIK3CA (0.47) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4342148 | 0.88 | PIK3CA (0.51) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4342144 | 0.88 | PIK3CA (0.52) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4350057 | 0.86 | PIK3CA (0.48) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4354797 | 0.86 | LMNA (0.46) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL4353807 | 0.85 | PIK3CA (0.45) | PIK3CAMAPK8MAPK9MAPK10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | claimed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | claimed |
| US-8604196-B2 | Modulating signal transduction pathways with 1-ethyl-3-[3-(1-methyl-1H-pyrazol-4-yl)-pyrido[2.3-B]pyrazine-6-yl]thiourea | AETERNA ZENTARIS GMBH (DE) | 2013-12-10 | — | — | US | disclosed |
| US-8536332-B2 | Modulating signal transduction pathways with substituted pyridol [2,3-b] pyrazines | AETERNA ZENTARIS GMBH (DE) | 2013-09-17 | — | — | US | disclosed |
| US-8507486-B2 | Pyridopyrazine derivatives, process of manufacturing and uses thereof | AETERNA ZENTARIS GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-11-01 | — | — | US | disclosed |
| US-20120214768-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-08-23 | — | — | US | disclosed |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | AETERNA ZENTARIS GMBH (DE) | 2012-08-16 | — | — | US | disclosed |
| US-8202883-B2 | Substituted pyrido[2,3-b]pyrazine compounds as modulators of tyrosine kinases | AETERNA ZENTARIS GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | ZENTARIS GMBH (DE) | 2009-11-05 | — | — | US | disclosed |
| EP-1990342-A1 | Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof | AEterna Zentaris GmbH (DE) | 2008-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214768-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | PIK3CA 537/4885MAPK8 1399/4885MAPK9 1346/4885 |
| US-20090275534-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | PIK3CA 537/4885MAPK8 1399/4885MAPK9 1346/4885 |
| US-20120277219-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | PIK3CA 537/4885MAPK8 1399/4885MAPK9 1346/4885 |
| US-20120209050-A1 | NOVEL PYRIDOPYRAZINE DERIVATIVES, PROCESS OF MANUFACTURING AND USES THEREOF | PNPO, PDXK, MKI67 | PIK3CA 537/4885MAPK8 1399/4885MAPK9 1346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.